Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Novel Insights and Advanced Research on Lung Cancer and COPD
- COPD 2019

Welcome Message

The 6th International Conference on Lung cancer and COPD is the world’s largest educational and scientific conference, dedicated to lung cancer and pulmonary diseases hosted on November 20-21 2019 Berlin, Germany. The congress summarizes the recent developments and advancements in lung cancer, COPD and pulmonary diseases research. The attendees of the conference include Medical OncologistsPulmonologistsEpidemiologistsSurgeonsPathologists, Research Scientists, Respiratory Physicians, Health Care Professionals and representatives from the academic and industrial experts.

Why to attend Lung Cancer and COPD Congress 2019?

Lung Cancer and COPD Congress 2019 provides a golden opportunity to meet the leading national and international speakers who will discuss the latest advancements in Lung cancer treatment, COPD, Pulmonary Diseases worldwide. COPD Conference 2019 unites individuals or eminent personalities from all over the world, who share a common discipline in lung diseases research. This conference is a collaborative event for the researchers from both business and academia background and offers current and recent information on the management of lung cancer, as well as the possible therapies and strategies to shape the future of lung cancer and COPD research. We encourage physicians, nurses, researchers and scientists as well as patients in the lung cancer field and those interested in attending to this Conference. It is only through an exchange of the widest variety of research we can offer the best program and benefits to our members and patients.

Abstract Submission & Important Dates

Abstract Submission Guidelines: 

The length of the abstract must not exceed 300 words.

The title should be in sentence case.

Should write name of the author and co-authors (if any).

You must provide your full name, affiliation (degree, institution/company/University name, address, contact number and email address).

Short biography of the author (limited to 100 words).

They must be submitted before the deadlines.

All the abstracts will be reviewed by the committee and you will get an email within 24-48 hours after submission of your abstract.

All the accepted abstracts will be published in the conference proceeding books.


Submit your Abstract: http://copd.alliedacademies.com/abstract-submission

 

Important Dates: 

Conference Dates :

November 20-21 2019

Abstract Submission ends:

September 25, 2019

Early bird Registration ends:

June 30, 2019



Register now: http://copd.alliedacademies.com/registration

Scientific Sessions

Session 1: Lung cancer

Cancerous tumour is a group of cancer cells that can grow into and destroy nearby tissue and can spread to other parts of the body. When cancer starts in lung cells, it is called as primary lung cancer. Cells in the lungs sometimes change and no longer grow or behave normally. These changes may lead to non-cancerous tumours such as hamartoma and papilloma.

Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC)
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 2:
Stages & Severity of Lung Diseases

There are two stages in small cell lung cancer. They are limited stage and extensive stage. Whereas non-small cell lung cancer is divided into four different stages depending upon the tumour size and location, number of nearby lymph nodes that have involved and how far the cancer has spread.

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 3:
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. It mainly affects middle-aged or older adults who smoke.it is not contagious. The breathing problems gradually worsen over time and can limit normal activities, particularly if smoking exposure continues increasing breathlessness.

Cough with phlegm
Frequent chest infections
Persistent wheezing
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 4:
Causes of COPD                                

Long-term exposure to lung irritants that damage the lungs and the airways is the main cause of COPD. Lungs may become inflamed and narrowed. The main cause is smoking, while in few cases it may be due to air pollution, chemical fumes and dust or occur as a result of a rare genetic problem.
Bronchitis
Emphysema
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 5:
Pathophysiology of Lung Cancer & COPD

Inflammation is present in the lungs of people who smoke. This response to the inhaled toxins is increased in COPD, leading to tissue destruction, impairment of the defence mechanisms and disruption of the repair mechanisms. In general, the inflammatory and structural changes in the airways increase with disease severity and persist even after the smoking cessation. Apart from inflammation, two processes are involved in the pathogenesis of COPD—an imbalance between proteases and antiproteases and an imbalance between oxidants and antioxidants in the lungs.
Tuberculosis
Pneumonia
Bronchiolitis
Ciliary dysfunction or primary ciliary dyskinesia (PCD)
Pulmonary hypertension
Hyperinflation
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings


Session 6:
Comorbidities of Pulmonary Diseases

COPD, like other chronic disorders, has been associated with comorbidities that increase in number and severity with age. Comorbidities increase the risk for exacerbations and increase the risk of mortality. Over 80% of patients with COPD were estimated to have at least one comorbid chronic condition. Comorbidities like diabetes mellitus, cardiac disease, osteoporosis, hypertension, cachexia, sleep disturbance, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD). Tobacco smoking is main risk factor for many of these comorbidities as well as for COPD.


COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings


Session 7:
Lung Diseases, Cancer & its Epidemiology

Chronic obstructive pulmonary disease is responsible for early mortality, high death rates and significant cost to health systems. The projection for 2020 indicates that COPD will be the third leading cause of death in the world.  Active smoking remains the main risk factor, but other factors such as occupational factors, infections and the role of air pollution also play a major role. Prevalence of COPD varies according to the country, age and sex. The major challenge in the coming years will be to prevent onset of smoking along with early detection of the disease in the population. An estimated 328 million people have COPD worldwide and in 15 years, COPD is expected to become the leading cause of death worldwide.


COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 8:
Diagnosis of COPD

The first and important step in diagnosing COPD is a thorough evaluation by an experienced doctor. There are different types of breathing tests that can be done during pulmonary function testing which helps the doctor to understand the severity of disease. Diagnosis of COPD involves:
Spirometry
Lung diffusion tests
Alpha-1- antitrypsin deficiency screening
Body plethysmography
Complete blood count
Pulse oximetry
Arterial blood gases
Chest x ray
CT scan
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
 Session 9:
Clinical Trials on COPD

Drug-treatment trials have allowed useful advances to be made in the treatment and diagnosis of chronic obstructive pulmonary disease (COPD). The two main clinical trial designs are randomized controlled trials (RCTs) and observational studies.  RCTs are generally considered to provide more robust evidence than that obtained from observational studies. However, well-designed comparator controlled RCTs, although successful, have been shown to have some limitations, such as a lack of generalizability. Observational studies can generate valuable data.

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 10:
Lung Cancer & Therapeutics

About one-third of lung cancer patients are diagnosed with localized disease that may be treated by either surgical resection or, if the patient is not a candidate for full surgical resection, with definitive radiotherapy Another third of patients have disease that has already spread to the lymph nodes. In these cases, radiation therapy along with chemotherapy and occasionally surgery is used.

Short acting bronchodilators
Corticosteroids
Protein kinase inhibitors
Methyl xanthine
Long acting bronchodilators
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 11:
Treatment Strategies of COPD

Most people have mild forms of the disease for which small therapy is needed. Even for more advanced stages of disease, effective therapy is available that can control symptoms, reduce risk of complications and exacerbations, and improve the ability to lead a healthy and active life. Treatment may differ from person to person. Treatment includes:
Smoking cessation
Medications
Phosphodiesterase-4 inhibitors
Theophylline
Antibiotics
Oxygen therapy
Pulmonary rehabilitation program
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 12:
Emerging Genetics of Lung Cancer & COPD

Mutational analysis and genomics profiling in recent years have advanced the field of lung cancer genetics significantly. It is becoming more accepted now that the identification of genomic alterations in lung cancer can impact therapeutics, especially when the alterations represent “oncogenic drivers” in the processes of tumorigenesis. Genetic testing is now a routine part of diagnosis and staging for every patient suffering with lung cancer and COPD. Genetics plays an important role as less than 20% of smokers develop this deadly disease in their lifetime and non-smokers with a family history of cancer have an increased risk of lung cancer.

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 13:
Risk Assessments on Lung Diseases

A risk factor is anything that affects a person’s chance of getting a disease. Lung cancer is the most frequent malignant neoplasm in most countries, and the main cancer-related cause of mortality worldwide. The geographic and temporal patterns of lung cancer incidence, as well as lung cancer mortality, on a population level are chiefly determined by tobacco consumption, the main aetiological factor in lung carcinogenesis.
Tobacco smoke
Exposure to radon
Exposure to asbestos
Inhaled chemicals
Air pollution
Family history


COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 14:
Diagnosis of Lung Cancer

Diagnosis is the process of finding out the cause of a health problem by performing various tests.
Chest X-ray
CT scan
PET-CT scan
Bronchoscopy and biopsy
Thoracentesis
Endoscopy
Sputum tests
 

COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings
 
Session 15:
Prevention and Awareness on COPD

Patients with chronic obstructive pulmonary disease require greater motivation to seek help when symptom changes occur and are unaware of their increased risk of developing lung cancer further. Prevention of COPD is very crucial. People with COPD have difficulty in clearing their lungs containing bacteria, dusts and other pollutants. This may lead to lung infections that may cause further damage to the lungs. With the advent of industrial control measures to minimize air levels, acute pulmonary syndromes have virtually disappeared in respective to COPD. 
Smoking cessation
Vaccinations like influenza vaccination and pneumococcal vaccine
Avoiding exposure to second-hand smoke
Protecting against chemicals, dust and fumes
 
COPD Conferences | Conferences on Lung Cancer | Cancer Conferences | Meetings on Pulmonary Diseases | Oncology Conferences | Congress on COPD | COPD| Lung Diseases | Cancer| Cancer Meetings

Market Analysis

       Importance & Scope of Lung Cancer And COPD Conference 2019

Lung cancer

The global lung cancer therapeutics market is expected to grow significantly in the future. North America dominated the global lung cancer therapeutics market over the past few years. The high demand in the region was sustained by factors which include increasing occurrences of lung cancer and rising levels of geriatric population. Asia-Pacific is projected to foresee the highest growth rate in the global lung cancer therapeutics market over the next eight years. Lung cancer is the leading cause of death in Europe, accounting for approximately 350 million deaths annually.

COPD

Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the asthma and chronic obstructive pulmonary disease (COPD) market globally. Worldwide US continent is the largest market for COPD. A recent market assessment study shows that COPD is the major cause of death, whose prevalence is on the rise and is predicted to be the third leading cause of death globally by 2030. Increase in commonness of COPD, increment in the geriatric populace and development of the pharmaceutical business are foreseen to fuel the development of COPD treatment market in Asia Pacific.

Major Medicine Universities:

Worldwide:

Harvard University

University of Minnesota

Pittsburgh School of Medicine

Mayo Medical School

Yale University 

John Hopkins University

The University of Oxford Stanford University

Emory University

University of Cambridge

 

In Asia Pacific:

The Chinese University of Hon Kong (CUHK)

Seoul National University

Tsinghua University

National Taiwan University

Peking University

Kyoto University

National University of Singapore (NUS)

Osaka University

University of Hong Kong (HKU)

 

Societies related to Cancer:

Europe:

Translational research in Oncology

Canceropole Ile-De-France

Institut Curie-Pole Developmental Biology

Saint- Louis Hospital

Bichat- Claude Bernard Hospital

Hartmann Clinic

Texas Oncology- Paris

Gustave Roussy Institute of Oncology

Hospital Group Paris Saint- Joseph

In Asia Pacific:

The Asia Pacific Urogynecology Association

Asian Cancer Foundation

Childhood Cancer International Netherlands

The Asia Pacific Prostate Society

The Max Foundation

The Asia Pacific Cancer Society Training

Worldwide:

Irish Cancer Society

Cancer Research UK

Peter McCollum Cancer Centre

American Society of Clinical Oncology (ASCO)

International Agency for Research on Cancer (IACR)

American Association for Cancer Research

International Cancer Research Partnership (ICRP)

National Cancer Institute (NIC)

The European Cancer Organization (ECCO)

 

Hospitals Associated with Cancer:

Japan:

Medical Excellence JAPAN

Japan Community Healthcare Organization Chukyo Hospital

Aichi Cancer Center Hospital

Kyoto University Hospital

Japanese Red Cross Nagoya Daiichi Hospital

Dokkyo Medical University Hospital

Japan Hospital Association

Aizawa Hospital

University Hospital Kumamoto University

International Medical Center of Japan

Europe:

Leiden University Medical Center

Royal Cancer Hospital

King’s College Hospital

Clattlerbridge Center for Oncology

Northampton General Hospital

Cambridge University Hospitals

University of Hospital Southhampton

Central Manchester University Hospitals

Southend University Hospital

Kingston Hospitals

USA:

New York Presbyterain Hospital

Memorial Sloan Kettering Cancer Center

Mayo Clinic Rochester

MD Anderson Cancer Center, Texas

John Hopkins Hospital, Baltimore

University of Washington Medical Center

Massachusetts General Hospital

UCSF Medical Center

UCLA Medical Center

Stanford Hospital 

Organizing Committee
OCM Member
Dr. Joe Nemeth
Emergency Medicine Physician/Trauma Team Leader, McGill University Health Centre
McGill University
Kelowna, Canada
OCM Member
John Klir
Dean and Professor, Physiology
American International Medical University
Washington, USA
OCM Member
Javier Mauricio Giraldo Sánchez
Doctor, Internal medicine
Medicina Intensiva del Tolima UCI Honda
Bogota, Colombia
OCM Member
Higinio Mappala, MD, FPCP, FPSG, DPBCN
Professor & Former Dean of 2 Medical Schools, Internal Medicine-Gastroenterology-Clinical Nutrition-Clinical Toxicology
Jose Reyes Mem. Medical Center
Quezon, Philippines
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date November 20-21, 2019
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality




Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program Inquiry
copd@alliedscholars.net
General Enquiry
copd@alliedscholars.com
Sponsorship Opportunity
copd@alliedglobalevents.com
More details about sponsorship:sponsors@alliedacademies.com

Highlights from last year's Convention

Authorization Policy

By registering for the conference you grant permission to Allied Academies to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.
Copyright © 2019-2020 Allied Academies, All Rights Reserved.